Inpharma 1396 - 19 Jul 2003

■ Adding BBR 2778 to a cytarabine,methylprednisolone plus cisplatin regimen isbeneficial in patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL), according to results froma phase I trial presented at the 32nd Annual Meetingof the International Society of ExperimentalHematology, held recently in Paris, France. The studyinvolved 19 such patients who were administeredopen-label BBR 2778* [‘Pixantrone’] 80 mg/m2 incombination with fixed doses of cytarabine,methylprednisolone plus cisplatin, as part of a 21-daycycle. The patients received a median of four cycles oftherapy. Of 18 evaluable patients, six achieved acomplete response to treatment and four achievedpartial responses. In addition, an unconfirmedcomplete response was observed in one patient andstable disease was observed in a further six patients.The overall response rate was 58% and the overalldisease control rate was > 90%. The therapeuticregimen was generally well tolerated.* phase III for non-Hodgkin’s lymphoma

Cell Therapeutics Inc. Preliminary Phase I Clinical Results of PixantronePresented at International Society of Experimental Hematology Meeting.Media Release : 7 Jul 2003. Available from: URL: http://www.cticseattle.com 809022899

1

Inpharma 19 Jul 2003 No. 13961173-8324/10/1396-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved